A Phase 3 interventional study of Deucravacitinib and Placebo in Psoriatic Arthritis, sponsored by Bristol-Myers Squibb. Active, not recruiting at 183 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb — 1 open to participants now, 3 under way, 3 of them phase 3. Arthritis, Psoriatic · Bristol-Myers Squibb.
Among the 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb, this one is one of 2 that started in 2021, is one of 4 in phase 3, and was the 8th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →1 of the 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb is open now. Recruiting first, the newest first:
Bristol-Myers Squibb
Ages 4–75
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 670 is above the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 203 across the 9 interventional studies, 38,396 across the 3 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety information.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Deucravacitinib
Other: Placebo
Specified dose on specified days
Also known as: BMS-986165
Specified dose on specified days
Percentage of Participants With ACR 20 Response at Week 16
The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 20% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.
Time frame: Week 16
Change From Baseline in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) at Week 16
DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \>5.1=high disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAS28-CRP indicates an improvement.
Time frame: Baseline and Week 16
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 16
HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in HAQ-DI indicates an improvement.
Time frame: Baseline and Week 16
Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 75 Response at Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline
PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.
Time frame: Week 16
Change From Baseline in the 36-item Short Form (SF-36) Physical Subcomponent Summary (PCS) Score at Week 16
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical subcomponent summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The scores range from 0 to 100, with a higher score indicating better quality of life. The PCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 PCS indicates an improvement.
Time frame: Baseline and Week 16
Percentage of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI) at Week 16
Percentage of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by Leeds Enthesitis Index (LEI). An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 enthesial sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.
Time frame: Week 16
Percentage of Participants Meeting Achievement of Minimal Disease Activity (MDA) at Week 16
Percentage of participants meeting achievement of MDA where an MDA response is achievement of 5 of 7 following outcomes at Week 16: 1. Tender joint count \<= 1 2. Swollen joint count \<=1 3. Psoriasis Area and Severity Index (PASI) \<= 1 or body surface area (BSA) \<= 3% 4. Patient assessment of psoriatic arthiritis (PsA) pain \<= 15 5. Patient Global Assessment of PsA disease activity \<= 20 6. HAQ-DI \<= 0.5 7. Tender enthesial points \<= 1
Time frame: Week 16
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score at Week 16
FACIT-Fatigue evaluates a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience or symptoms of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The recall period is 7 days. Each item is rated on a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very much." Sum scores for the 13 items range from 0 through 52, where higher scores indicate less fatigue. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in FACIT-Fatigue indicates an improvement.
Time frame: Baseline and Week 16
Percentage of Participants Meeting Dactylitis Resolution at Week 16
Percentage of participants meeting dactylitis resolution at Week 16 among the participants with dactylitis at baseline, where resolution is defined as a tender dactylitis count of 0 in participants with a tender dactylitis count =\> 1 at baseline. The number of digits in hands and feet with dactylitis will be counted by a blinded assessor.
Time frame: Week 16
Change From Baseline in PsA-modified Sharp-van Der Heijde (SvdH) Score at Week 16
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. Change from baseline reflects progression or improvement; a decrease suggests reduced damage or improvement.
Time frame: Baseline and Week 16
Percentage of Participants With ACR 20 Response up to Week 16
The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 20% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.
Time frame: Week 2, 4, 8, 12, and 16
Percentage of Participants With ACR 50 Response up to Week 16
The ACR 50 definition of improvement is a 50% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 50% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.
Time frame: Week 2, 4, 8, 12, and 16
Percentage of Participants With ACR 70 Response up to Week 16
The ACR 70 definition of improvement is a 70% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 70% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.
Time frame: Week 2, 4, 8, 12, and 16
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) up to Week 16
HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in HAQ-DI indicates an improvement.
Time frame: Baseline and Week 2, 4, 8, 12, and 16
Percentage of Participants Who Achieve a Clinically Meaningful Improvement in Health Assessment Questionnaire - Disability Index (HAQ-DI) up to Week 16 Among Participants With a HAQ-DI Score ≥0.35 at Baseline
HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Clinically meaningful improvement was defined as ≥0.35improvement from baseline.
Time frame: Baseline and Week 2, 4, 8, 12, and 16
Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 75 Response up to Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline
PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.
Time frame: Week 4, 8, 12 and 16
Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 90 Response up to Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline
PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 is the number of participants who experience at least a 90% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.
Time frame: Week 4, 8, 12 and 16
Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 100 Response up to Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline
PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 100 is the number of participants who experience at least a 100% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.
Time frame: Week 4, 8, 12 and 16
Change From Baseline in the 36-item Short Form (SF-36) Physical Subcomponent Summary (PCS) Score up to Week 16
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical subcomponent summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The scores range from 0 to 100, with a higher score indicating poor quality of life. The PCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 PCS indicates an improvement.
Time frame: Baseline and Week 4, 12 and 16
Percentage of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI) up to Week 16
Percentage of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by Leeds Enthesitis Index (LEI). An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 enthesial sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.
Time frame: Week 4, 8, 12 and 16
Percentage of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Spondyloarthritis Research Consortium of Canada (SPARCC) up to Week 16
Percentage of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by SPARCC. The SPARCC Enthesitis Index has a 0 to 16 score that is derived from the evaluation of 8 locations: the greater trochanter (right \\\[R\\\]/left \\\[L\\\]), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L), and supraspinatus insertion (R/L). A higher count indicates a higher enthesitis burden based on the current evaluation.
Time frame: Week 4, 8, 12 and 16
Percentage of Participants Meeting Achievement of Minimal Disease Activity (MDA) up to Week 16
Percentage of participants meeting achievement of MDA where an MDA response is achievement of 5 of 7 following outcomes at Week 16: 1. Tender joint count \<= 1 2. Swollen joint count \<=1 3. Psoriasis Area and Severity Index (PASI) \<= 1 or body surface area (BSA) \<= 3% 4. Patient assessment of psoriatic arthiritis (PsA) pain \<= 15 5. Patient Global Assessment of PsA disease activity \<= 20 6. HAQ-DI \<= 0.5 7. Tender enthesial points \<= 1
Time frame: Week 4, 8, 12, and 16
Change From Baseline in the 36-item Short Form (SF-36) Mental Component Summary (MCS) Score up to Week 16
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The mental component summary (MCS) of the SF-36 consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. The scores range from 0 to 100, with a higher score indicating poor quality of life. The MCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 MCS indicates an improvement.
Time frame: Baseline and Week 4, 12 and 16
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score up to Week 16
FACIT-Fatigue evaluates a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience or symptoms of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The recall period is 7 days. Each item is rated on a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very much." Sum scores for the 13 items range from 0 through 52, where higher scores indicate less fatigue. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in FACIT-Fatigue indicates an improvement.
Time frame: Baseline and Week 2, 4, 8, 12 and 16
Percentage of Participants Meeting Dactylitis Resolution up to Week 16
Percentage of participants meeting dactylitis resolution at Week 16 among the participants with dactylitis at baseline, where resolution is defined as a tender dactylitis count of 0 in participants with a tender dactylitis count =\> 1 at baseline. The number of digits in hands and feet with dactylitis will be counted by a blinded assessor.
Time frame: Week 4, 8, 12 and 16
Change From Baseline in Psoriatic Arthritis Impact of Disease (PsAID) 12 Score up to Week 16
The Psoriatic Arthritis Impact of Disease (PsAID) is a 12-item self-report that measures PsA symptoms and impact of disease. Each item is scored on a 0 to 10 numeric rating scale with a 1-week recall period. The PsAID has a total score, with a higher value indicating worse health. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in PsAID indicates an improvement.
Time frame: Baseline and Week 2, 4, 8, 12 and 16
Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) Score up to Week 16
The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \\\[cm\\\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. The DAPSA score ranges from 0 to 154, with a higher score indicating more disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAPSA indicates an improvement.
Time frame: Baseline and Week 2, 4, 8, 12 and 16
Percentage of Participants With Achievement of Disease Activity Index for Psoriatic Arthritis (DAPSA) Low Disease Activity Response up to Week 16
The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \\\[cm\\\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity.
Time frame: Baseline and Week 2, 4, 8, 12 and 16
Percentage of Participants With Achievement of Disease Activity Index for Psoriatic Arthritis (DAPSA) Disease Remission up to Week 16
The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \\\[cm\\\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity. A score 0 signifies remission.
Time frame: Baseline and Week 2, 4, 8, 12 and 16
Percentage of Participants Meeting Achievement of Physician Global Assessment-Fingernails (PGA-F) of 0/1 up to Week 16
The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe. The overall condition of the fingernails is rated on a 5-point scale: 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, and 4 = severe.
Time frame: Week 2, 4, 8, 12 and 16
Change From Baseline in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) up to Week 16
DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \\\< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \\\>5.1=high disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAS28-CRP indicates an improvement.
Time frame: Baseline and Week 2, 4, 8, 12 and 16
Percentage of Participants Meeting Disease Activity Score 28 C-reactive Protein (DAS28-CRP) Low Disease Activity Response up to Week 16
DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \\\< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \\\>5.1=high disease activity.
Time frame: Week 2, 4, 8, 12 and 16
Percentage of Participants Meeting Disease Activity Score 28 C-reactive Protein (DAS28-CRP) Disease Remission up to Week 16
DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \\\< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \\\>5.1=high disease activity.
Time frame: Week 2, 4, 8, 12 and 16
Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) up to Week 16
The Psoriatic Arthritis Disease Activity Score (PASDAS) is a composite measure calculated from the Physician Global Assessment of PsA, the Participant Global Assessment of Disease Activity, the Short Form-36 PCS, the swollen joint count, the tender joint count, the Enthesitis (LEI), the Dactylitis (LDI) (Basic), and the High-sensitivity C-reactive protein (hsCRP). The range of PASDAS is 0-10. Higher score means more active disease. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.
Time frame: Baseline and Week 4, 12 and 16
Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) up to Week 16
Four domains are used to calculate the modified Composite Psoriatic Disease Activity Index (mCPDAI): joints (66 swollen joint count and 68 tender joint count; Health Assessment Questionnaire), skin (PASI and DLQI), dactylitis (a simple count of each digit involved), and enthesitis (number of tendons/fascia insertion sites showing enthesitis scored from 0 to 4, based on palpation of Achilles tendon and bilateral plantar fasciae insertion). The mCPDAI is scored using a 4 point scale from 0 (no disease activity) to 3 (most severe disease activity), giving an mCPDAI score range of 0 through 12. A higher score indicates more active disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.
Time frame: Baseline and Week 4, 8, 12 and 16
Percentage of Participants With Achievement of Psoriatic Arthritis Response Criteria (PsARC) up to Week 16
The Psoriatic Arthritis Response Criteria (PsARC) consists of 4 measurements: tender joint count, swollen joint count, Physician Global Assessment of PsA, and Participant Global Assessment of Disease Activity. In order to be classified as a PsARC responder, participants must achieve improvement in 2 of 4 measures, 1 of which must be joint pain or swelling, without worsening in any measure. Improvement in each of the measures is defined below: 1) Decrease of ≥ 30% in tender joint counts; 2) Decrease of ≥ 30% in swollen joint counts; 3) Decrease of ≥ 20% in Physician Global Assessment of PsA; 4) Decrease of ≥ 20% in Participant's Global Assessment of Disease Activity
Time frame: Week 2, 4, 8, 12 and 16
Percentage of Participants Meeting Achievement of Improvement of Bath Ankylosing Spondylitis Disease Activity (BASDAI) Score up to Week 16
BASDAI consists of a 0 to 10 scale measuring discomfort, pain, and fatigue in response to 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: 1) Fatigue (medical); 2) Spinal pain; 3) Joint pain and swelling; 4) Areas of localized tenderness; 5) Morning stiffness duration; 6) Morning stiffness severity. A higher count indicates worse disease. Each individual question response is scaled to a 0-10 score by dividing by 10, and the BASDAI is derived using the following formula: BASDAI = ((Q1 + Q2 + Q3 + Q4) + ((Q5 + Q6) / 2)) / 5
Time frame: Week 2, 4, 8, 12 and 16
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= 0 at Week 16
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.
Time frame: Week 16
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= 0.5 at Week 16
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.
Time frame: Week 16
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= Smallest Detectable Change (SDC) at Week 16
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. SDC is calculated as 1.96\* standard deviation of the paired differences of change from baseline/ square root of (2\*k); k is the number of reviewers and is default to 2 in this study.
Time frame: Week 16
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= 0 at Week 16
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.
Time frame: Week 16
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= 0.5 at Week 16
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.
Time frame: Week 16
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= SDC at Week 16
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. SDC is calculated as 1.96\* standard deviation of the paired differences of change from baseline/ square root of (2\*k); k is the number of reviewers and is default to 2 in this study.
Time frame: Week 16
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= 0 at Week 16
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.
Time frame: Week 16
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= 0.5 at Week 16
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.
Time frame: Week 16
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= SDC at Week 16
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. SDC is calculated as 1.96\* standard deviation of the paired differences of change from baseline/ square root of (2\*k); k is the number of reviewers and is default to 2 in this study.
Time frame: Week 16
Change From Baseline in PsA-modified SvdH Erosion Scores Response at Week 16
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.
Time frame: Baseline and Week 16
Change From Baseline in PsA-modified SvdH JSN Scores Response at Week 16
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.
Time frame: Baseline and Week 16
Change From Baseline in the 36-item Short Form (SF-36) Physical Subcomponent Summary Score up to Week 16
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical sub component is one of the 4 subscales of PCS. The physical subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 physical sub-component indicates an improvement.
Time frame: Baseline and Week 4, 12 and 16
Change From Baseline in the 36-item Short Form (SF-36) Role Activity Subcomponent Summary Score up to Week 16
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The role activity sub component is one of the 4 subscales of PCS. The role activity subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 role activity indicates an improvement.
Time frame: Baseline and Week 4, 12 and 16
Change From Baseline in the 36-item Short Form (SF-36) Bodily Pain Subcomponent Summary Score up to Week 16
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The bodily pain sub component is one of the 4 subscales of PCS. The bodily pain subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 bodily pain subcomponent indicates an improvement.
Time frame: Baseline and Week 4, 12 and 16
Change From Baseline in the 36-item Short Form (SF-36) General Health Perceptions Subcomponent Summary Score up to Week 16
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The general health perceptions sub component is one of the 4 subscales of PCS. The general health perceptions subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 general health perceptions subcomponent indicates an improvement.
Time frame: Baseline and Week 4, 12 and 16
Change From Baseline in the 36-item Short Form (SF-36) Vitality Subcomponent Score up to Week 16
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The vitality subcomponent is one of the 4 subscales of MCS. The vitality subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 vitality subcomponent indicates an improvement.
Time frame: Baseline and Week 4, 12 and 16
Change From Baseline in the 36-item Short Form (SF-36) Social Subcomponent Score up to Week 16
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The social subcomponent is one of the 4 subscales of MCS. The social subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 social subcomponent indicates an improvement.
Time frame: Baseline and Week 4, 12 and 16
Change From Baseline in the 36-item Short Form (SF-36) Mental Health Subcomponent Score up to Week 16
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The mental health subcomponent is one of the 4 subscales of MCS. The mental health subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 mental health subcomponent indicates an improvement.
Time frame: Baseline and Week 4, 12 and 16
Change From Baseline in the 36-item Short Form (SF-36) Emotional Problems Subcomponent Score up to Week 16
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The emotional problem subcomponent is one of the 4 subscales of MCS. The emotional problem subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 emotional problems subcomponent indicates an improvement.
Time frame: Baseline and Week 4, 12 and 16
Change From Baseline in the Work Productivity and Activity Impairment (WPAI) Subcomponents Score at Week 16
WPAI contains 4 subcomponents - absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity (overall work impairment/absenteeism plus presenteeism), and activity impairment. Each subcomponent score ranges from 0 to 100, with higher numbers indicating worse outcome. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.
Time frame: Baseline and week 16
Change From Baseline in the European Quality of Life 5D-5L (EQ-5D-5L) Utility Scores and Its Subcomponents up to 16
The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. Change from Baseline in 5-level EuroQol 5-dimension (EQ-5D-5L) Utility Scores. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.
Time frame: Baseline and week 4 and 16
Change From Baseline in Patient-Reported Outcome Measures Information System (PROMIS) Sleep Disturbance up to Week 16
The Patient-Reported Outcome Measures Information System Sleep Disturbance assess self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This includes perceived difficulties and concerns with getting to sleep or staying asleep, as well as perceptions of the adequacy of and satisfaction with sleep. The items are evaluated on a 5-point Likert scale ranging from 1 = "not at all" to 5 = "very much" with a 7-day recall period. Higher score means more active disease. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.
Time frame: Baseline and week 4, 12, and 16
| Milestone | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo | Active Treatment Period - Deucravacitinib 6 mg QD | Active-Treatment Period - Placebo-Deucravacitinib 6 mg QD |
|---|---|---|---|---|
| Started | 336 | 334 | 0 | 0 |
| Completed | 332 | 333 | 0 | 0 |
| Not completed | 4 | 1 | 0 | 0 |
| Withdrew: Other reasons | 3 | 1 | 0 | 0 |
| Withdrew: Participant withdrew consent | 1 | 0 | 0 | 0 |
| Milestone | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo | Active Treatment Period - Deucravacitinib 6 mg QD | Active-Treatment Period - Placebo-Deucravacitinib 6 mg QD |
|---|---|---|---|---|
| Started | 332 | 333 | 0 | 0 |
| Completed | 309 | 306 | 0 | 0 |
| Not completed | 23 | 27 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 2 | 0 | 0 |
| Withdrew: Adverse event | 8 | 6 | 0 | 0 |
| Withdrew: Participant request to discontinue study treatment | 2 | 3 | 0 | 0 |
| Withdrew: Participant withdrew consent | 4 | 10 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Withdrew: Administrative reasons by sponsor | 0 | 1 | 0 | 0 |
| Withdrew: Other reasons | 8 | 4 | 0 | 0 |
| Milestone | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo | Active Treatment Period - Deucravacitinib 6 mg QD | Active-Treatment Period - Placebo-Deucravacitinib 6 mg QD |
|---|---|---|---|---|
| Started | 0 | 0 | 309 | 306 |
| Completed | 0 | 0 | 168 | 160 |
| Not completed | 0 | 0 | 141 | 146 |
| Withdrew: Other reasons | 0 | 0 | 1 | 3 |
| Withdrew: Lack of efficacy | 0 | 0 | 4 | 5 |
| Withdrew: Adverse event | 0 | 0 | 5 | 8 |
| Withdrew: Participant request to discontinue study treatment | 0 | 0 | 2 | 2 |
| Withdrew: Participant withdrew consent | 0 | 0 | 8 | 11 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 2 |
| Withdrew: Poor/non-compliance | 0 | 0 | 1 | 0 |
| Withdrew: Administrative reasons by sponsor | 0 | 0 | 1 | 1 |
| Withdrew: Ongoing treatment | 0 | 0 | 117 | 114 |
The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 20% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Percentage of Participants With ACR 20 Response at Week 16 | 54.2 (48.7 to 59.6) | 34.1 (29.1 to 39.5) |
DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \>5.1=high disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAS28-CRP indicates an improvement.
| Score on a Scale | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Change From Baseline in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) at Week 16 | -1.4106 ± 1.13277 | -0.8902 ± 1.10750 |
HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in HAQ-DI indicates an improvement.
| Score on a Scale | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 16 | -0.4103 ± 0.52303 | -0.2118 ± 0.51583 |
PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 75 Response at Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline | 51.9 (43.9 to 59.8) | 7.1 (3.7 to 12.0) |
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical subcomponent summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The scores range from 0 to 100, with a higher score indicating better quality of life. The PCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 PCS indicates an improvement.
| Score on a Scale | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Change From Baseline in the 36-item Short Form (SF-36) Physical Subcomponent Summary (PCS) Score at Week 16 | 6.410 ± 8.2883 | 3.847 ± 7.2929 |
Percentage of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by Leeds Enthesitis Index (LEI). An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 enthesial sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Percentage of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI) at Week 16 | 48.3 (40.8 to 55.9) | 46.1 (38.4 to 54.0) |
Percentage of participants meeting achievement of MDA where an MDA response is achievement of 5 of 7 following outcomes at Week 16: 1. Tender joint count \<= 1 2. Swollen joint count \<=1 3. Psoriasis Area and Severity Index (PASI) \<= 1 or body surface area (BSA) \<= 3% 4. Patient assessment of psoriatic arthiritis (PsA) pain \<= 15 5. Patient Global Assessment of PsA disease activity \<= 20 6. HAQ-DI \<= 0.5 7. Tender enthesial points \<= 1
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Percentage of Participants Meeting Achievement of Minimal Disease Activity (MDA) at Week 16 | 19.0 (15.0 to 23.7) | 10.2 (7.2 to 13.9) |
FACIT-Fatigue evaluates a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience or symptoms of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The recall period is 7 days. Each item is rated on a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very much." Sum scores for the 13 items range from 0 through 52, where higher scores indicate less fatigue. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in FACIT-Fatigue indicates an improvement.
| Score on a Scale | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score at Week 16 | 4.9 ± 8.84 | 2.2 ± 8.81 |
Percentage of participants meeting dactylitis resolution at Week 16 among the participants with dactylitis at baseline, where resolution is defined as a tender dactylitis count of 0 in participants with a tender dactylitis count =\> 1 at baseline. The number of digits in hands and feet with dactylitis will be counted by a blinded assessor.
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Percentage of Participants Meeting Dactylitis Resolution at Week 16 | 59.1 (50.2 to 67.6) | 43.5 (34.0 to 53.4) |
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. Change from baseline reflects progression or improvement; a decrease suggests reduced damage or improvement.
| Score on a Scale | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Change From Baseline in PsA-modified Sharp-van Der Heijde (SvdH) Score at Week 16 | 0.3980 ± 2.00852 | 0.5757 ± 2.73874 |
The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 20% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 2 | 14.0 (10.5 to 18.2) | 13.8 (10.3 to 17.9) |
| Week 4 | 31.5 (26.6 to 36.8) | 19.5 (15.4 to 24.1) |
| Week 8 | 42.6 (37.2 to 48.0) | 30.5 (25.6 to 35.8) |
| Week 12 | 49.1 (43.6 to 54.6) | 31.1 (26.2 to 36.4) |
| Week 16 | 54.2 (48.7 to 59.6) | 34.1 (29.1 to 39.5) |
The ACR 50 definition of improvement is a 50% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 50% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 2 | 2.1 (0.8 to 4.2) | 1.2 (0.3 to 3.0) |
| Week 4 | 7.7 (5.1 to 11.1) | 3.6 (1.9 to 6.2) |
| Week 8 | 17.0 (13.1 to 21.4) | 9.6 (6.6 to 13.3) |
| Week 12 | 22.6 (18.3 to 27.5) | 10.8 (7.7 to 14.6) |
| Week 16 | 24.7 (20.2 to 29.7) | 13.5 (10.0 to 17.6) |
The ACR 70 definition of improvement is a 70% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 70% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 2 | 0.3 (0.0 to 1.6) | 0.0 (0.0 to 1.1) |
| Week 4 | 1.8 (0.7 to 3.8) | 0.0 (0.0 to 1.1) |
| Week 8 | 5.7 (3.4 to 8.7) | 3.0 (1.4 to 5.4) |
| Week 12 | 7.4 (4.9 to 10.8) | 3.6 (1.9 to 6.2) |
| Week 16 | 11.6 (8.4 to 15.5) | 5.4 (3.2 to 8.4) |
HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in HAQ-DI indicates an improvement.
| Score on a Scale | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 2 (n=324, 323) | -0.1655 ± 0.37744 | -0.1250 ± 0.38243 |
| Week 4 (n=325, 326) | -0.2412 ± 0.43862 | -0.1614 ± 0.39402 |
| Week 8 (n=327, 326) | -0.3119 ± 0.50219 | -0.1963 ± 0.47057 |
| Week 12 (n= 326, 327) | -0.3589 ± 0.49384 | -0.1957 ± 0.53080 |
| Week 16 (n=326, 327) | -0.4103 ± 0.52303 | -0.2118 ± 0.51583 |
HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Clinically meaningful improvement was defined as ≥0.35improvement from baseline.
| Percentage of Participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 2 | 28.0 (23.1 to 33.3) | 28.0 (23.1 to 33.4) |
| Week 4 | 41.4 (35.9 to 47.1) | 30.9 (25.8 to 36.4) |
| Week 8 | 45.5 (39.9 to 51.2) | 34.2 (28.9 to 39.8) |
| Week 12 | 49.7 (44.0 to 55.4) | 39.7 (34.2 to 45.5) |
| Week 16 | 51.3 (45.6 to 56.9) | 38.8 (33.3 to 44.5) |
PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 4 | 11.7 (7.2 to 17.7) | 6.5 (3.3 to 11.3) |
| Week 8 | 31.5 (24.4 to 39.2) | 10.0 (5.9 to 15.5) |
| Week 12 | 42.6 (34.9 to 50.6) | 8.8 (5.0 to 14.1) |
| Week 16 | 51.9 (43.9 to 59.8) | 7.1 (3.7 to 12.0) |
PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 is the number of participants who experience at least a 90% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 4 | 4.3 (1.8 to 8.7) | 1.8 (0.4 to 5.1) |
| Week 8 | 14.8 (9.7 to 21.2) | 1.8 (0.4 to 5.1) |
| Week 12 | 20.4 (14.5 to 27.4) | 3.5 (1.3 to 7.5) |
| Week 16 | 25.3 (18.8 to 32.7) | 1.8 (0.4 to 5.1) |
PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 100 is the number of participants who experience at least a 100% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 4 | 1.9 (0.4 to 5.3) | 1.2 (0.1 to 4.2) |
| Week 8 | 8.0 (4.3 to 13.3) | 0.6 (0.0 to 3.2) |
| Week 12 | 11.1 (6.7 to 17.0) | 1.8 (0.4 to 5.1) |
| Week 16 | 14.2 (9.2 to 20.5) | 1.8 (0.4 to 5.1) |
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical subcomponent summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The scores range from 0 to 100, with a higher score indicating poor quality of life. The PCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 PCS indicates an improvement.
| Score on a Scale | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 4 | 3.760 ± 6.2768 | 3.326 ± 5.7315 |
| Week 12 | 6.021 ± 7.5809 | 3.916 ± 7.6614 |
| Week 16 | 6.410 ± 8.2883 | 3.847 ± 7.2929 |
Percentage of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by Leeds Enthesitis Index (LEI). An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 enthesial sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 4 | 31.5 (24.7 to 38.8) | 32.9 (25.9 to 40.6) |
| Week 8 | 44.4 (37.0 to 52.0) | 47.9 (40.1 to 55.8) |
| Week 12 | 47.2 (39.7 to 54.8) | 50.3 (42.5 to 58.1) |
| Week 16 | 48.3 (40.8 to 55.9) | 46.1 (38.4 to 54.0) |
Percentage of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by SPARCC. The SPARCC Enthesitis Index has a 0 to 16 score that is derived from the evaluation of 8 locations: the greater trochanter (right \\\[R\\\]/left \\\[L\\\]), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L), and supraspinatus insertion (R/L). A higher count indicates a higher enthesitis burden based on the current evaluation.
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 4 | 19.4 (14.4 to 25.4) | 25.6 (19.8 to 32.0) |
| Week 8 | 34.7 (28.4 to 41.5) | 30.8 (24.6 to 37.5) |
| Week 12 | 36.6 (30.1 to 43.4) | 34.6 (28.2 to 41.4) |
| Week 16 | 45.8 (39.1 to 52.7) | 34.1 (27.8 to 40.9) |
Percentage of participants meeting achievement of MDA where an MDA response is achievement of 5 of 7 following outcomes at Week 16: 1. Tender joint count \<= 1 2. Swollen joint count \<=1 3. Psoriasis Area and Severity Index (PASI) \<= 1 or body surface area (BSA) \<= 3% 4. Patient assessment of psoriatic arthiritis (PsA) pain \<= 15 5. Patient Global Assessment of PsA disease activity \<= 20 6. HAQ-DI \<= 0.5 7. Tender enthesial points \<= 1
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 4 | 6.0 (3.7 to 9.0) | 3.0 (1.4 to 5.4) |
| Week 8 | 10.1 (7.1 to 13.9) | 6.6 (4.2 to 9.8) |
| Week 12 | 14.0 (10.5 to 18.2) | 7.2 (4.7 to 10.5) |
| Week 16 | 19.0 (15.0 to 23.7) | 10.2 (7.2 to 13.9) |
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The mental component summary (MCS) of the SF-36 consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. The scores range from 0 to 100, with a higher score indicating poor quality of life. The MCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 MCS indicates an improvement.
| Score on a Scale | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 4 | 0.814 ± 7.5082 | 0.634 ± 7.3796 |
| Week 12 | 2.056 ± 8.4206 | 0.034 ± 8.3926 |
| Week 16 | 2.588 ± 8.3442 | 0.358 ± 8.1559 |
FACIT-Fatigue evaluates a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience or symptoms of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The recall period is 7 days. Each item is rated on a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very much." Sum scores for the 13 items range from 0 through 52, where higher scores indicate less fatigue. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in FACIT-Fatigue indicates an improvement.
| Score on a Scale | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 2 | 2.2 ± 7.31 | 2.3 ± 6.52 |
| Week 4 | 2.5 ± 7.48 | 2.3 ± 7.67 |
| Week 8 | 4.5 ± 8.68 | 2.8 ± 9.64 |
| Week 12 | 4.3 ± 8.98 | 1.8 ± 8.97 |
| Week 16 | 4.9 ± 8.84 | 2.2 ± 8.81 |
Percentage of participants meeting dactylitis resolution at Week 16 among the participants with dactylitis at baseline, where resolution is defined as a tender dactylitis count of 0 in participants with a tender dactylitis count =\> 1 at baseline. The number of digits in hands and feet with dactylitis will be counted by a blinded assessor.
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 4 | 36.4 (28.2 to 45.2) | 33.3 (24.6 to 43.1) |
| Week 8 | 44.7 (36.0 to 53.6) | 43.5 (34.0 to 53.4) |
| Week 12 | 54.5 (45.7 to 63.2) | 48.1 (38.4 to 58.0) |
| Week 16 | 59.1 (50.2 to 67.6) | 43.5 (34.0 to 53.4) |
The Psoriatic Arthritis Impact of Disease (PsAID) is a 12-item self-report that measures PsA symptoms and impact of disease. Each item is scored on a 0 to 10 numeric rating scale with a 1-week recall period. The PsAID has a total score, with a higher value indicating worse health. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in PsAID indicates an improvement.
| Score on a Scale | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 2 | -0.807 ± 1.3327 | -0.652 ± 1.2524 |
| Week 4 | -1.164 ± 1.5433 | -0.836 ± 1.5580 |
| Week 8 | -1.545 ± 1.9037 | -0.991 ± 1.9281 |
| Week 12 | -1.761 ± 2.0074 | -0.883 ± 1.9677 |
| Week 16 | -1.851 ± 2.0440 | -1.015 ± 1.9955 |
The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \\\[cm\\\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. The DAPSA score ranges from 0 to 154, with a higher score indicating more disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAPSA indicates an improvement.
| Score on a Scale | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 2 | -7.6211 ± 13.23221 | -7.0045 ± 11.71166 |
| Week 4 | -12.5643 ± 14.38734 | -10.1201 ± 13.64766 |
| Week 8 | -16.6770 ± 16.71038 | -12.3610 ± 15.70632 |
| Week 12 | -19.8346 ± 17.22613 | -13.2671 ± 17.41524 |
| Week 16 | -20.7263 ± 18.08249 | -13.4075 ± 17.31116 |
The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \\\[cm\\\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity.
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 2 | 6.5 (4.1 to 9.7) | 4.5 (2.5 to 7.3) |
| Week 4 | 13.7 (10.2 to 17.8) | 9.9 (6.9 to 13.6) |
| Week 8 | 21.4 (17.2 to 26.2) | 16.5 (12.7 to 20.9) |
| Week 12 | 28.9 (24.1 to 34.0) | 17.4 (13.5 to 21.9) |
| Week 16 | 26.2 (21.6 to 31.2) | 18.9 (14.8 to 23.5) |
The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \\\[cm\\\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity. A score 0 signifies remission.
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 2 | 0.3 (0.0 to 1.6) | 0.0 (0.0 to 1.1) |
| Week 4 | 1.5 (0.5 to 3.4) | 0.6 (0.1 to 2.1) |
| Week 8 | 3.0 (1.4 to 5.4) | 1.8 (0.7 to 3.9) |
| Week 12 | 5.7 (3.4 to 8.7) | 1.8 (0.7 to 3.9) |
| Week 16 | 8.6 (5.9 to 12.2) | 2.7 (1.2 to 5.1) |
The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe. The overall condition of the fingernails is rated on a 5-point scale: 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, and 4 = severe.
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 4 | 12.7 (6.0 to 22.7) | 6.6 (1.8 to 15.9) |
| Week 8 | 19.7 (11.2 to 30.9) | 16.4 (8.2 to 28.1) |
| Week 12 | 16.9 (9.0 to 27.7) | 21.3 (11.9 to 33.7) |
| Week 16 | 23.9 (14.6 to 35.5) | 14.8 (7.0 to 26.2) |
DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \\\< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \\\>5.1=high disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAS28-CRP indicates an improvement.
| Score on a Scale | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 2 | -0.4028 ± 0.77126 | -0.4006 ± 0.70508 |
| Week 4 | -0.7655 ± 0.90092 | -0.6468 ± 0.82146 |
| Week 8 | -1.0820 ± 1.02041 | -0.7727 ± 0.99752 |
| Week 12 | -1.3360 ± 1.13745 | -0.8450 ± 1.09776 |
| Week 16 | -1.4106 ± 1.13277 | -0.8902 ± 1.10750 |
DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \\\< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \\\>5.1=high disease activity.
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 2 | 5.4 (3.2 to 8.3) | 4.8 (2.8 to 7.7) |
| Week 4 | 9.8 (6.9 to 13.5) | 6.0 (3.7 to 9.1) |
| Week 8 | 11.3 (8.1 to 15.2) | 9.3 (6.4 to 12.9) |
| Week 12 | 14.3 (10.7 to 18.5) | 11.7 (8.4 to 15.6) |
| Week 16 | 15.2 (11.5 to 19.5) | 8.1 (5.4 to 11.5) |
DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \\\< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \\\>5.1=high disease activity.
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 2 | 2.1 (0.8 to 4.2) | 2.1 (0.8 to 4.3) |
| Week 4 | 8.0 (5.4 to 11.5) | 5.4 (3.2 to 8.4) |
| Week 8 | 14.9 (11.3 to 19.1) | 8.7 (5.9 to 12.2) |
| Week 12 | 20.8 (16.6 to 25.6) | 9.0 (6.1 to 12.6) |
| Week 16 | 22.3 (18.0 to 27.2) | 13.8 (10.3 to 17.9) |
The Psoriatic Arthritis Disease Activity Score (PASDAS) is a composite measure calculated from the Physician Global Assessment of PsA, the Participant Global Assessment of Disease Activity, the Short Form-36 PCS, the swollen joint count, the tender joint count, the Enthesitis (LEI), the Dactylitis (LDI) (Basic), and the High-sensitivity C-reactive protein (hsCRP). The range of PASDAS is 0-10. Higher score means more active disease. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.
| Score on a Scale | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 4 | -1.0405 ± 1.03004 | -0.8258 ± 0.97038 |
| Week 12 | -1.7675 ± 1.37563 | -1.0780 ± 1.33036 |
| Week 16 | -1.9064 ± 1.45258 | -1.1026 ± 1.31166 |
Four domains are used to calculate the modified Composite Psoriatic Disease Activity Index (mCPDAI): joints (66 swollen joint count and 68 tender joint count; Health Assessment Questionnaire), skin (PASI and DLQI), dactylitis (a simple count of each digit involved), and enthesitis (number of tendons/fascia insertion sites showing enthesitis scored from 0 to 4, based on palpation of Achilles tendon and bilateral plantar fasciae insertion). The mCPDAI is scored using a 4 point scale from 0 (no disease activity) to 3 (most severe disease activity), giving an mCPDAI score range of 0 through 12. A higher score indicates more active disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.
| Score on a Scale | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 4 | -1.2 ± 1.81 | -0.8 ± 1.61 |
| Week 8 | -1.7 ± 2.09 | -1.2 ± 1.89 |
| Week 12 | -2.1 ± 2.16 | -1.3 ± 2.01 |
| Week 16 | -2.2 ± 2.22 | -1.3 ± 1.96 |
The Psoriatic Arthritis Response Criteria (PsARC) consists of 4 measurements: tender joint count, swollen joint count, Physician Global Assessment of PsA, and Participant Global Assessment of Disease Activity. In order to be classified as a PsARC responder, participants must achieve improvement in 2 of 4 measures, 1 of which must be joint pain or swelling, without worsening in any measure. Improvement in each of the measures is defined below: 1) Decrease of ≥ 30% in tender joint counts; 2) Decrease of ≥ 30% in swollen joint counts; 3) Decrease of ≥ 20% in Physician Global Assessment of PsA; 4) Decrease of ≥ 20% in Participant's Global Assessment of Disease Activity
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 2 | 25.9 (21.3 to 30.9) | 21.9 (17.5 to 26.7) |
| Week 4 | 47.0 (41.6 to 52.5) | 31.1 (26.2 to 36.4) |
| Week 8 | 51.5 (46.0 to 56.9) | 41.3 (36.0 to 46.8) |
| Week 12 | 55.4 (49.9 to 60.8) | 39.8 (34.5 to 45.3) |
| Week 16 | 62.5 (57.1 to 67.7) | 40.1 (34.8 to 45.6) |
BASDAI consists of a 0 to 10 scale measuring discomfort, pain, and fatigue in response to 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: 1) Fatigue (medical); 2) Spinal pain; 3) Joint pain and swelling; 4) Areas of localized tenderness; 5) Morning stiffness duration; 6) Morning stiffness severity. A higher count indicates worse disease. Each individual question response is scaled to a 0-10 score by dividing by 10, and the BASDAI is derived using the following formula: BASDAI = ((Q1 + Q2 + Q3 + Q4) + ((Q5 + Q6) / 2)) / 5
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 2 | 7.3 (2.0 to 17.6) | 6.1 (1.3 to 16.9) |
| Week 4 | 10.9 (4.1 to 22.2) | 16.3 (7.3 to 29.7) |
| Week 8 | 18.2 (9.1 to 30.9) | 14.3 (5.9 to 27.2) |
| Week 12 | 25.5 (14.7 to 39.0) | 16.3 (7.3 to 29.7) |
| Week 16 | 25.5 (14.7 to 39.0) | 14.3 (5.9 to 27.2) |
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= 0 at Week 16 | 59.5 (54.1 to 64.8) | 53.9 (48.4 to 59.3) |
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= 0.5 at Week 16 | 62.8 (57.4 to 68.0) | 60.5 (55.0 to 65.8) |
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. SDC is calculated as 1.96\* standard deviation of the paired differences of change from baseline/ square root of (2\*k); k is the number of reviewers and is default to 2 in this study.
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= Smallest Detectable Change (SDC) at Week 16 | 67.6 (62.3 to 72.5) | 66.2 (60.8 to 71.2) |
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= 0 at Week 16 | 60.4 (55.0 to 65.7) | 56.6 (51.1 to 62.0) |
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= 0.5 at Week 16 | 64.3 (58.9 to 69.4) | 62.9 (57.4 to 68.1) |
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. SDC is calculated as 1.96\* standard deviation of the paired differences of change from baseline/ square root of (2\*k); k is the number of reviewers and is default to 2 in this study.
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= SDC at Week 16 | 66.7 (61.3 to 71.7) | 66.8 (61.4 to 71.8) |
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= 0 at Week 16 | 67.6 (62.3 to 72.5) | 64.4 (59.0 to 69.5) |
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= 0.5 at Week 16 | 70.5 (65.3 to 75.4) | 68.9 (63.6 to 73.8) |
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. SDC is calculated as 1.96\* standard deviation of the paired differences of change from baseline/ square root of (2\*k); k is the number of reviewers and is default to 2 in this study.
| percentage of participants | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= SDC at Week 16 | 70.5 (65.3 to 75.4) | 68.9 (63.6 to 73.8) |
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.
| Score on a Scale | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Change From Baseline in PsA-modified SvdH Erosion Scores Response at Week 16 | 0.32 ± 1.417 | 0.37 ± 1.326 |
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.
| Score on a Scale | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Change From Baseline in PsA-modified SvdH JSN Scores Response at Week 16 | 0.09 ± 0.703 | 0.14 ± 0.485 |
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical sub component is one of the 4 subscales of PCS. The physical subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 physical sub-component indicates an improvement.
| Score on a Scale | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 4 | 7.923 ± 17.9483 | 6.908 ± 17.0306 |
| Week 12 | 13.615 ± 20.5725 | 7.784 ± 22.4709 |
| Week 16 | 15.414 ± 22.3930 | 8.226 ± 22.1449 |
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The role activity sub component is one of the 4 subscales of PCS. The role activity subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 role activity indicates an improvement.
| Score on a Scale | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 4 | 6.962 ± 20.6963 | 7.058 ± 18.7454 |
| Week 12 | 13.096 ± 22.7372 | 8.365 ± 21.1286 |
| Week 16 | 13.152 ± 23.6370 | 7.913 ± 20.8035 |
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The bodily pain sub component is one of the 4 subscales of PCS. The bodily pain subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 bodily pain subcomponent indicates an improvement.
| Score on a Scale | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 4 | 10.0 ± 16.52 | 8.5 ± 15.47 |
| Week 12 | 16.6 ± 20.96 | 9.4 ± 19.66 |
| Week 16 | 18.2 ± 21.83 | 10.0 ± 18.85 |
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The general health perceptions sub component is one of the 4 subscales of PCS. The general health perceptions subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 general health perceptions subcomponent indicates an improvement.
| Score on a Scale | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 4 | 6.1 ± 12.95 | 5.1 ± 13.35 |
| Week 12 | 8.4 ± 15.13 | 4.8 ± 15.02 |
| Week 16 | 8.9 ± 16.00 | 4.6 ± 14.85 |
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The vitality subcomponent is one of the 4 subscales of MCS. The vitality subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 vitality subcomponent indicates an improvement.
| Score on a Scale | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 4 | 4.558 ± 14.6829 | 4.327 ± 14.3971 |
| Week 12 | 8.442 ± 17.9283 | 4.308 ± 17.6763 |
| Week 16 | 9.682 ± 16.4474 | 4.893 ± 17.5265 |
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The social subcomponent is one of the 4 subscales of MCS. The social subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 social subcomponent indicates an improvement.
| Score on a Scale | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 4 | 6.69 ± 20.610 | 4.62 ± 20.737 |
| Week 12 | 11.96 ± 23.990 | 4.88 ± 22.539 |
| Week 16 | 13.80 ± 22.960 | 4.74 ± 23.303 |
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The mental health subcomponent is one of the 4 subscales of MCS. The mental health subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 mental health subcomponent indicates an improvement.
| Score on a Scale | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 4 | 2.1 ± 14.17 | 2.2 ± 13.99 |
| Week 12 | 4.9 ± 16.41 | 1.4 ± 16.38 |
| Week 16 | 5.5 ± 15.98 | 1.5 ± 15.78 |
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The emotional problem subcomponent is one of the 4 subscales of MCS. The emotional problem subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 emotional problems subcomponent indicates an improvement.
| Score on a Scale | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 4 | 2.718 ± 20.1133 | 2.128 ± 20.1154 |
| Week 12 | 5.846 ± 21.4070 | 0.718 ± 21.0925 |
| Week 16 | 7.438 ± 22.6517 | 2.370 ± 21.4931 |
WPAI contains 4 subcomponents - absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity (overall work impairment/absenteeism plus presenteeism), and activity impairment. Each subcomponent score ranges from 0 to 100, with higher numbers indicating worse outcome. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.
| Score on a Scale | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| WPAI Absenteeism | -3.30 ± 20.777 | 1.23 ± 19.389 |
| WPAI Presenteeism | -13.76 ± 23.299 | -6.91 ± 20.332 |
| Work Productivity | -13.33 ± 24.053 | -6.80 ± 21.526 |
| WPAI Activity Impairment | -15.20 ± 25.466 | -9.69 ± 23.855 |
The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. Change from Baseline in 5-level EuroQol 5-dimension (EQ-5D-5L) Utility Scores. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.
| Score on a Scale | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Utility Score (Week 4) | 0.1006 ± 0.19470 | 0.0694 ± 0.19282 |
| Utility Score (Week 16) | 0.1630 ± 0.23696 | 0.0721 ± 0.23083 |
| Mobility (Week 4) | -0.3 ± 0.77 | -0.3 ± 0.80 |
| Mobility (Week 16) | -0.5 ± 0.88 | -0.3 ± 0.92 |
| Self-Care (Week 4) | -0.3 ± 0.81 | -0.2 ± 0.78 |
| Self-Care (Week 16) | -0.5 ± 0.90 | -0.1 ± 0.86 |
| Usual Activities (Week 4) | -0.3 ± 0.83 | -0.3 ± 0.71 |
| Usual Activities (Week 16) | -0.5 ± 0.92 | -0.3 ± 0.78 |
| Pain/Discomfort (Week 4) | -0.4 ± 0.77 | -0.3 ± 0.81 |
| Pain/Discomfort (Week 16) | -0.6 ± 0.93 | -0.3 ± 0.92 |
| Anxiety/Depression (Week 4) | -0.2 ± 0.74 | -0.1 ± 0.79 |
| Anxiety/Depression (Week 16) | -0.3 ± 0.84 | -0.1 ± 0.91 |
The Patient-Reported Outcome Measures Information System Sleep Disturbance assess self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This includes perceived difficulties and concerns with getting to sleep or staying asleep, as well as perceptions of the adequacy of and satisfaction with sleep. The items are evaluated on a 5-point Likert scale ranging from 1 = "not at all" to 5 = "very much" with a 7-day recall period. Higher score means more active disease. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.
| Score on a Scale | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo |
|---|---|---|
| Week 4 | -1.48 ± 6.489 | -1.09 ± 6.413 |
| Week 12 | -2.46 ± 8.196 | -0.88 ± 8.177 |
| Week 16 | -3.15 ± 7.761 | -1.59 ± 7.645 |
Collected over All-cause mortality and Adverse events were collected from first dose (Day 1) and up to 30 days after the last dose of treatment in the study (up to approximately 164 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo-Controlled Period - Deucravacitinib 6 mg QD | 0/336 (0%) | 6/332 (1.8%) | 39/332 (11.7%) |
| Placebo-Controlled Period - Placebo | 0/334 (0%) | 8/333 (2.4%) | 32/333 (9.6%) |
| Active Treatment Period - Deucravacitinib 6 mg QD | 0/309 (0%) | 21/309 (6.8%) | 68/309 (22%) |
| Active-Treatment Period - Placebo-Deucravacitinib 6 mg QD | 0/306 (0%) | 17/306 (5.6%) | 67/306 (21.9%) |
| Event | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo | Active Treatment Period - Deucravacitinib 6 mg QD | Active-Treatment Period - Placebo-Deucravacitinib 6 mg QD |
|---|---|---|---|---|
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/332 | 0/333 | 2/309 | 0/306 |
| Angina unstableCardiac disorders | 0/332 | 0/333 | 0/309 | 1/306 |
| Atrial fibrillationCardiac disorders | 0/332 | 1/333 | 0/309 | 1/306 |
| Hiatus herniaGastrointestinal disorders | 0/332 | 0/333 | 0/309 | 1/306 |
| CholelithiasisHepatobiliary disorders | 0/332 | 0/333 | 1/309 | 1/306 |
| Drug hypersensitivityImmune system disorders | 0/332 | 0/333 | 0/309 | 1/306 |
| COVID-19 pneumoniaInfections and infestations | 0/332 | 0/333 | 0/309 | 1/306 |
| Hepatitis infectious mononucleosisInfections and infestations | 0/332 | 0/333 | 0/309 | 1/306 |
| Herpes zoster disseminatedInfections and infestations | 0/332 | 0/333 | 0/309 | 1/306 |
| Oral candidiasisInfections and infestations | 0/332 | 0/333 | 0/309 | 1/306 |
| Event | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo | Active Treatment Period - Deucravacitinib 6 mg QD | Active-Treatment Period - Placebo-Deucravacitinib 6 mg QD |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 17/332 | 10/333 | 32/309 | 33/306 |
| NasopharyngitisInfections and infestations | 13/332 | 12/333 | 24/309 | 26/306 |
| HypertensionVascular disorders | 10/332 | 10/333 | 18/309 | 14/306 |
| Age, Continuous(years) | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo | Total |
|---|---|---|---|
| Mean | 51.7 ± 12.52 | 52.3 ± 12.32 | 52.0 ± 12.41 |
| Sex: Female, Male(Participants) | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo | Total |
|---|---|---|---|
| Female | 164 | 170 | 334 |
| Male | 172 | 164 | 336 |
| Ethnicity (NIH/OMB)(Participants) | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 101 | 94 | 195 |
| Not Hispanic or Latino | 165 | 165 | 330 |
| Unknown or Not Reported | 70 | 75 | 145 |
| Race/Ethnicity, Customized(Participants) | Placebo-Controlled Period - Deucravacitinib 6 mg QD | Placebo-Controlled Period - Placebo | Total |
|---|---|---|---|
| WHITE | 263 | 279 | 542 |
| BLACK OR AFRICAN AMERICAN | 4 | 1 | 5 |
| AMERICAN INDIAN OR ALASKA NATIVE | 17 | 19 | 36 |
| OTHER | 27 | 21 | 48 |
| CHINESE | 24 | 14 | 38 |
| ASIAN OTHER | 1 | 0 | 1 |
Showing the first 100 of 183 sites across 21 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Jul 2021 to primary completion in Oct 2024, 38 months.
Results were first posted in Oct 2025, 1 year after primary completion.
Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 38 months is above that.
Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.
Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2024 → Oct 2024, on Oct 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deucravacitinib